von 1,30 Euro auf 4,70 Euro in 1 Jahr ist "ungesund" - trotz aller Eurphorie und guten Aussichten finde ich den jetzigen Kurs angemessener....immerhin ist hier der Blockbuster noch 1-2 Jahre weg. Antares macht ca. 25 Mio USD Umsatz, muss deswegen aber nicht 600 Mio USD teuer sein... Zocker raus und Investoren rein...in diesem Sinne..:-) Q2 Ergebnisse: EWING, NJ, August 8, 2012 --
Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the second quarter ended June 30, 2012. Quarter and Recent Highlight
Completed the VIBEX™ MTX Actual Human Use study. Results from this study will be available early in the fourth quarter. The New Drug Application (NDA) filing remains on track for first quarter 2013 as all studies necessary for the completion of the NDA are now fully enrolled. Announced positive results from the VIBEX™ MTX human factors usability study. The study demonstrated that lay caregivers, healthcare professionals and rheumatoid arthritis patients with severe to very severe hand function impairment could administer simulated injections successfully with our VIBEX™ device. Announced in April the launch of Gelnique 3%™ for the treatment of overactive bladder by our partner Watson as well as the settlement of the epinephrine auto-injector litigation between Pfizer and our partner Teva. Increased total revenue 28% and 60% to $4.5 million and $11.4 million in the three and six mont periods ended June 30, 2012, respectively, from $3.5 million and $7.1 million, respectively, in the comparable periods of the prior year. Ended the quarter with approximately $33 million in cash and investments and no debt. |
